Document is current
Any future updates will be listed below
-
Authors
Xavier, Camila B.
Gouda, Mohamed A.
Tsimberidou, Apostolia M.
-
Funding
Funding for this research was provided by:
National Institutes of Health/National Cancer Institute (P30 CA016672)
- License Information
-
More Information
Article History
Received: 23 January 2025
Accepted: 8 September 2025
First Online: 9 October 2025
Competing interests
: Apostolia M. Tsimberidou declares receipt of Clinical Trial Research Funding (received through the institution): Immatics (Inst), OBI Pharma (Inst), Tempus (Inst), Parker Institute for Cancer Immunotherapy (Inst), Agenus (Inst), Novocure (Inst), Tvardi Therapeutics (Inst), Orionis (Inst), Tachyon (Inst), Vividion Therapeutics (Inst), AbbVie (Inst), Macrogenics (Inst), Anaveon (Inst); and has consulting/advisory roles for Nex-I, BrYet, OBI Pharma. The remaining authors declare no competing interests.
